|
Jun 12
|
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
|
|
May 15
|
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
|
|
Apr 17
|
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years
|
|
Apr 3
|
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
|
|
Apr 1
|
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
|
|
Feb 13
|
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake
|